Xia Luo

2.9k total citations · 2 hit papers
48 papers, 1.9k citations indexed

About

Xia Luo is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Xia Luo has authored 48 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 19 papers in Molecular Biology and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Xia Luo's work include Cancer Immunotherapy and Biomarkers (11 papers), Economic and Financial Impacts of Cancer (10 papers) and Lung Cancer Treatments and Mutations (8 papers). Xia Luo is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Economic and Financial Impacts of Cancer (10 papers) and Lung Cancer Treatments and Mutations (8 papers). Xia Luo collaborates with scholars based in China, Australia and United States. Xia Luo's co-authors include Qianjin Liao, Linda Oyang, Yujuan Zhou, Longzheng Xia, Yanyan Tang, Shiming Tan, Jinguan Lin, Yaqian Han, Jiaxin Liang and Min Su and has published in prestigious journals such as PLoS ONE, Cancer and Oncogene.

In The Last Decade

Xia Luo

46 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The cancer metabolic reprogramming and immune response

2021 799 citations Longzheng Xia, Linda Oyang et al. Molecular Cancer profile →
Endoplasmic reticulum stress—a key guardian in cancer

2024 62 citations Wenlong Zhang, Yidan Shi et al. Cell Death Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xia Luo China	20	936	697	619	454	315	48	1.9k
Jonathan Krell United Kingdom	29	1.4k 1.5×	1.3k 1.9×	814 1.3×	278 0.6×	195 0.6×	126	2.6k
Liangfang Shen China	24	946 1.0×	598 0.9×	390 0.6×	202 0.4×	131 0.4×	77	1.5k
Chenyue Zhang China	22	680 0.7×	465 0.7×	578 0.9×	303 0.7×	198 0.6×	74	1.4k
Daniele Fanale Italy	29	1.2k 1.3×	922 1.3×	979 1.6×	437 1.0×	274 0.9×	84	2.5k
Hao‐Xiang Wu China	22	520 0.6×	393 0.6×	596 1.0×	289 0.6×	251 0.8×	38	1.3k
Ben Markman Australia	24	1.3k 1.4×	329 0.5×	1.2k 2.0×	489 1.1×	219 0.7×	75	2.5k
Shaoquan Zheng China	26	1.4k 1.4×	1.0k 1.5×	646 1.0×	537 1.2×	262 0.8×	51	2.2k
Geny Piro Italy	25	808 0.9×	341 0.5×	684 1.1×	260 0.6×	260 0.8×	59	1.6k
Sonia V. del Rincón Canada	23	1.3k 1.4×	309 0.4×	731 1.2×	152 0.3×	456 1.4×	59	2.1k
Shundong Cang China	21	1.4k 1.5×	485 0.7×	779 1.3×	679 1.5×	194 0.6×	80	2.3k

Countries citing papers authored by Xia Luo

Since Specialization

Citations

This map shows the geographic impact of Xia Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xia Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xia Luo more than expected).

Fields of papers citing papers by Xia Luo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xia Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xia Luo. The network helps show where Xia Luo may publish in the future.

Co-authorship network of co-authors of Xia Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Xia Luo. A scholar is included among the top collaborators of Xia Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xia Luo. Xia Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Qiu, Peng, Lujuan Wang, Ying Long, et al.. (2025). SRSF9 mediates oncogenic RNA splicing of SLC37A4 via liquid–liquid phase separation to promote oral cancer progression. Journal of Advanced Research. 79. 505–520. 3 indexed citations

Chen, Yunliang, Pengcheng Li, Meng Zhao, et al.. (2024). Liquiritin improves macrophage degradation of engulfed tumour cells by promoting the formation of phagolysosomes via NOX2/gp91phox. Journal of Pharmaceutical Analysis. 15(5). 101093–101093.

Jiang, Xianjie, Qiu Peng, Mingjing Peng, et al.. (2024). Cellular metabolism: A key player in cancer ferroptosis. Cancer Communications. 44(2). 185–204. 36 indexed citations

Jiang, Xianjie, Mingjing Peng, Qiang Liu, et al.. (2024). Circular RNA hsa_circ_0000467 promotes colorectal cancer progression by promoting eIF4A3-mediated c-Myc translation. Molecular Cancer. 23(1). 151–151. 13 indexed citations

Zhang, Wenlong, Yidan Shi, Linda Oyang, et al.. (2024). Endoplasmic reticulum stress—a key guardian in cancer. Cell Death Discovery. 10(1). 343–343. 62 indexed citations breakdown →

Ye, Peng, Liting Wang, Liubao Peng, et al.. (2023). Cost-effectiveness of Trastuzumab Deruxtecan for HER2-low Advanced Breast Cancer in the United States. Clinical Therapeutics. 45(10). 965–972. 3 indexed citations

Luo, Xia, Qiao Liu, Zhen Zhou, et al.. (2022). Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer. Frontiers in Pharmacology. 13. 832215–832215. 12 indexed citations

Ye, Peng, Xiaohui Zeng, Liubao Peng, et al.. (2022). Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Frontiers in Pharmacology. 13. 778505–778505. 19 indexed citations

Liu, Qiao, Zhen Zhou, Xia Luo, et al.. (2022). Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%. Frontiers in Pharmacology. 12. 803626–803626. 5 indexed citations

10.

Liu, Qiao, Xia Luo, Zhen Zhou, et al.. (2021). PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC： A Cost-Effectiveness Analysis in China. Frontiers in Oncology. 11. 745493–745493. 3 indexed citations

11.

Ye, Peng, Xiaohui Zeng, Liubao Peng, et al.. (2021). Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy. Frontiers in Oncology. 11. 743765–743765. 4 indexed citations

12.

Tan, Chongqing, Xia Luo, Sini Li, et al.. (2021). Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis. Clinical Rheumatology. 41(1). 63–73. 4 indexed citations

13.

Ye, Peng, Xiaohui Zeng, Liubao Peng, et al.. (2021). Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer. Advances in Therapy. 38(7). 3962–3972. 12 indexed citations

14.

Zeng, Xiaohui, Qiao Liu, Peng Ye, et al.. (2021). Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma. Advances in Therapy. 38(5). 2379–2390. 1 indexed citations

15.

Qiu, Peng, Yujuan Zhou, Linda Oyang, et al.. (2021). Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics. Molecular Therapy. 30(3). 1018–1035. 44 indexed citations

16.

Li, Sini, Liubao Peng, Chongqing Tan, et al.. (2020). Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China. PLoS ONE. 15(5). e0232240–e0232240. 22 indexed citations

17.

Liu, Qiao, Xia Luo, Liubao Peng, et al.. (2020). Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China. BMJ Open. 10(11). e040691–e040691. 8 indexed citations

18.

Wang, Ying, Nayiyuan Wu, Xia Luo, et al.. (2019). SOX2OT, a novel tumor-related long non-coding RNA. Biomedicine & Pharmacotherapy. 123. 109725–109725. 26 indexed citations

19.

Tan, Chongqing, Liubao Peng, Xiaohui Zeng, et al.. (2013). Economic Evaluation of First-Line Adjuvant Chemotherapies for Resectable Gastric Cancer Patients in China. PLoS ONE. 8(12). e83396–e83396. 11 indexed citations

20.

Wan, Xiaomin, Chongqing Tan, Jonathan Karnon, et al.. (2009). Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective. PharmacoEconomics. 27(10). 873–886. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact